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INTRODUCTION
Polymyositis (PM) and dermatomyositis (DM) are
systemic inflammatory disorders affecting skeletal
muscles and other organs (1). PM/DM are associ-
ated with high morbidity and mortality rates related
to muscle weakness, cardiac and lung involvement
(2). Interstitial pneumonia (IP) is one of the most fre-
quent and serious organ involvements in patients with
PM/DM (3). The first line of treatment in PM/DM
is considered to consist of corticosteroids which con-
tinue to be the mainstay of treatment in most pa-
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tients with PM/DM. The use of methylprednisolone
(mPSL) pulse can be an effective and rapidly-acting
treatment in severe cases (4). When medication of
corticosteroids alone is not effective, the use of im-
munosuppressive agents combined with corticoster-
oids is selected (5-7). Recent reports have shown
that the corticosteroid-resistant IP is successfully
treated with cyclosporin A, a T-cell specific immuno-
suppressant (5, 7). However, the immunosuppres-
sive medications are mainly implicated in high fre-
quency of infections in patients with PM/DM (8).
Recent studies have shown that there are his-
tologic and immunologic differences between PM
and DM, suggesting that therapeutic approaches
and prognosis may be different. For example, the
complication of IP was more frequent in DM pa-
tients than in PM patients (6), and the risk of ma-
lignant diseases is greater in DM than in PM (10,
11). This study evaluated the prevalence, clinical fea-
tures and outcome of patients with PM/DM com-
paring PM and DM.
PATIENTS AND METHODS
Patients
Twenty-three PM/DM patients who had been
admitted to our clinical department of Tokushima
University Hospital between 2000 and 2006 were
included in this study. Diagnosis of PM/DM was
made according to the criteria by Bohan and Peter
(12, 13) when clinical data fulfilled 4 or 5 of the cri-
teria. Table 1 shows baseline patient characteristics.
Patients consisted of 9 PM (2 males and 7 females)
aged 5414 years on average and 14 DM (4 males
and 10 females) aged 5414 years on average. The
association of other collagen vascular diseases (CVD)
was seen in 2 patients with PM (SLE/SjS/RA, RA)
and in a patient with DM (SjS). Anti-Jo1 antibody
was positive in 2 patients with PM and a patient
with DM. IP was diagnosed just before the initial
treatment by a reticulonodular pattern on the chest
radiograph and high-resolution computed tomogra-
phy (HRCT), by decreased PaO2 levels (less than
80 mmHg) without PaCO2 elevation in arterial blood,
and by a restrictive pattern and a decrease in dif-
fusing capacity for carbon monoxide in pulmonary
function test. HRCT was available for all patients to
investigate radiographic abnormalities. Since HRCT
has been shown to be able to suggest the underly-
ing pathologic category (14), the diagnosis of usual
interstitial pneumonia (UIP) pattern, non-specific
interstitial pneumonia (NSIP) pattern, organizing
pneumonia (OP) pattern and diffuse alveolar dam-
age (DAD) pattern was performed based on the
HRCT characteristics. The characteristic HRCT fea-
tures of UIP are predominantly basal and peripheral
reticular pattern with honeycombing and traction
bronchiectasis. NSIP is characterized by predomi-
nantly basal ground-glass opacity and/or reticular
pattern, often with traction bronchiectasis. OP is
characterized by patchy peripheral or peribroncho-
vascular consolidation. DAD manifests as diffuse
lung consolidation and ground-glass opacity. Other
clinical data collected from records of patients in-
cluded regimen of PM/DM therapy.
Statistical analysis
All results are expressed as meanSD. Statisti-
cal analyses were performed using Statview software.
The results were regarded as significant when p
value was0.05.
RESULTS
Complications
The clinical features and course were compared
between patients with PM (Table 2) and DM (Table
3). Muscular symptoms were seen in all patients
with PM, and 71% of patients with DM. There was
no significant difference between patients with PM
(78%) and DM (86%) in % of patients with elevated
CK (Table 1). The complication of IP was found in
17 patients (74%) ; 56 % of PM patients and 86% of
DM patients (Table 1, 2 and 3). HRCT showed that
Table 1. Baseline patient characteristics
PM DM
Number of patients 9 14
Sex (M / F) 2 / 7 4 / 10
Average age 5414 5414
Other collagen vascular disease 2
(SLE /SjS /RA) (RA)
1
(SjS)
Interstitial pneumonia (+) 5 (56) 12 (86)
Anti-Jo 1 antibody (+) 2 (22) 1 (7)
Elevation of CK 7 (78) 12 (86)
Elevation of CRP 4 (44) 9 (64)
Elevation of KL-6 5 (56) 8 (57)
Parentheses show percentage, Values express as meanSD.
Ages at the initial treatment were shown.
CK ; creatine kinase, CRP ; c-reactive protein, PM ; polymyosi-
tis, DM ; dermatomyositis,
SjS ; Sjogren’s syndrome, SLE ; systemic lupus erythematosus,
RA ; rheumatoid arthritis
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UIP pattern was found in 4 patients, NSIP pattern in
11 patients, and OP pattern in 2 patients (Table 4).
DAD pattern appeared in a patient with DM who had
originally showed NSIP pattern (Case 12). The level
of KL-6 before the therapy was higher in patients
with UIP pattern than in patients with NSIP pattern
though there was no significant difference. The pres-
ence of anti-Jo1 antibody has been shown to be
highly associated with IP in PM/DM patients (3),
but this study failed to demonstrate the interaction
of the presence of IP and anti-Jo1 antibody because
of the limited number of patients we enrolled and
a few frequency of positive anti-Jo1 antibody in our
patients. PM/DM frequently occurs in overlap with
CVD (1). In our cases, the association of other CVD
was seen in 2 patients with PM (SLE/SjS/RA, RA)
and in a patient with DM (SjS).
Treatment
Twenty-one patients (91%) with PM/DM re-
ceived high dose of corticosteroids using predni-
solone (Table 2, 3 and 5). High dose prednisolone
therapy was performed in 7 PM patients (78%) and
in all of DM patients. Ten patients (42%) with PM/
DM received cyclosporin A. More patients were
treated with cyclosporin A in DM patients (57%)
than in PM patients (22%). Muscular lesions were
improved by the therapy in all of PM/DM patients
Table 2. PM patients
Case
No. Age/sex
Other collagen
vascular disease
Interstitial
pneumonia
Elevation
of CK
Anti-Jo1
antibody PSL mPSL CyA Prognosis
1 63/F () UIP () ( + ) () () () Improved (M)
2 61/F () OP () () ( + ) () () Improved (M, P)
3 54/F RA UIP ( + ) () ( + ) () ( + ) Improved (M, P)
4 57/F () NSIP ( + ) () ( + ) () ( + ) Improved (M, P)
5 29/F SLE, RA, SjS () ( + ) () ( + ) ( + ) () Improved (M)
6 41/F () () ( + ) ( + ) ( + ) () () Improved (M)
7 50/M () () ( + ) () ( + ) () () Improved (M)
8 69/M () NSIP ( + ) () () () () Improved (M)
9 58/F () () ( + ) () ( + ) () () Improved (M)
PM ; polymyositis, SLE ; systemic lupus erythematosus, RA ; rheumatoid arthritis, SjS ; Sjogren’s syndrome, UIP ; usual interstitial
pneumonia, OP ; organizing pneumonia, NSIP ; non-specific interstitial pneumonia, PSL ; prednisolone, mPSL ; methylprednisolone,
CyA ; cyclosporin A, M ; muscular lesion, P ; pulmonary lesion
Table 3. DM patients
Case
No. Age/sex
Other
collagen
disease
Interstitial
pneumonia
Muscular
symptoms
Elevation
of CK
Anti-Jo1
antibody PSL mPSL CyA Prognosis
10 34/F () NSIP ( + ) ( + ) () ( + ) () () Improved (M, P)
11 56/F () NSIP () ( + ) () ( + ) ( + ) ( + ) Improved (M)
12 62/F () NSIP* () ( + ) () ( + ) ( + ) ( + ) Died
13 48/F () NSIP () () () ( + ) ( + ) ( + ) Improved (P)
14 37/F SjS NSIP ( + ) ( + ) () ( + ) ( + ) ( + ) Improved (M, P)
15 55/F () UIP ( + ) ( + ) () ( + ) () () Improved (M, P)
16 70/F () NSIP () () () ( + ) () () Improved (P)
17 55/F () OP ( + ) ( + ) ( + ) ( + ) () ( + ) Improved (M, P)
18 49/F () UIP ( + ) ( + ) () ( + ) ( + ) ( + ) Improved (M, P)
19 34/M () NSIP ( + ) ( + ) () ( + ) ( + ) ( + ) Improved (M, P)
20 76/M () () ( + ) ( + ) () ( + ) () () Died
21 67/M () NSIP ( + ) ( + ) () ( + ) () () Improved (M, P)
22 64/M () NSIP ( + ) ( + ) () ( + ) () ( + ) Improved (M, P)
23 67/F () () ( + ) ( + ) () ( + ) () () Improved (M)
DM ; dermatomyositis, SjS ; Sjogren’s syndrome, NSIP ; non-specific interstitial pneumonia, DAD ; diffuse alveolar damage, UIP ;
usual interstitial pneumonia, OP ; organizing pneumonia, CK ; creatine kinase, PSL ; prednisolone, mPSL ; methylprednisolone, CyA ;
cyclosporin A, M ; muscular lesion, P ; pulmonory lesion
*NSIP pattern changed into DAD pattern in clinical course.
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who had them before the treatment. HRCT findings
showed that the improvement of IP was observed
in 13 patients (76%) of 17 PM/DM patients with
IP ; 60 % of PM patients and 83% of DM patients.
Seven (29%) of patients with PM/DM were treated
with mPSL pulse as an initial therapy (Table 6). The
percentage of PM patients was lower in patients
treated with mPSL pulse (14%) than in those with-
out mPSL pulse (50%). Patients who were treated
with mPSL pulse were significantly younger than
those without mPSL pulse. There was no difference
in the complication of diabetes mellitus, severe in-
fections, or aseptic necrosis of the femoral head after
the therapy between patients treated with mPSL
Table 6. Comparison of clinical course between patients with and without methylprednisolone pulse therapy
mPSL
pulse
therapy
Number
of
patients
%PM Age Sex(M/F)
Muscular
improvement
pulmonary
improvement Complications
Muscular
symptoms CK HRCT KL-6 Diabetes
Serious
complic-
ation
Aseptic necrosis
of the femoral
head
+ 7 14 4512 1/6 4(100)
6
(100)
4
(67)
3
(50)
1
(14)
2
(29)
1
(14)
 16 50 5911* 4/12 15(100)
13
(100)
9
(100)
5
(56)
4**
(25)
5
(31)
0
(0)
Parentheses show percentage, Values express as meanSD.
%PM =(the number of PM patients/ the number of total patients)100,
mPSL ; methylprednisolone, CK ; creatine kinase, HRCT ; high-resolution computed tomography
* p=0.04, ** A patient was complicated before the treatment.
Table 5. Treatment
Number
of
patients
Sex
(M/F) Age %PM
Muscular
improvement
Pulmonary
improvement
Muscular
symptoms CK HRCT KL-6
prednisolone alone 11 3/8 5516 45 10(100)
9
(100)
5
(100)
2
(67)
prednisolone
+ cyclosporin A
(at the same time)
4 0/4 5111 0 2(100)
3
(100)
3
(75)
3
(100)
prednisolne
+ cyclosporin A
(on the way)
6 2/4 5210 33 5(100)
6
(100)
5
(83)
3
(60)
Parentheses show percentage, Values express as meanSD.
%PM =(the number of PM patients/the number of total patients)100, CK ; creatine kinase, HRCT ; high-resolution computed to-
mography
Table 4. Clinical findings of interstitial pneumonia
Interstitial
pneumonia
Classified
in HRCT
Number of
patients PM/DM
KL-6
(U/ml)
Muscular
symptoms
( + )
Elevation
of CK
( + )
Combination
mPSL pulse CyA
 6 4/2 22654 6(100)
6
(100)
1
(17)
0
(0)
+
UIP pattern 4 2/2 23843072 4(100)
3
(75)
1
(25)
1
(25)
NSIP pattern 11* 2/9 620231 7(64)
9
(82)
5
(45)
8
(73)
DAD pattern 0*
OP pattern 2 1/1 16501429 2(100)
1
(50)
0
(0)
1
(50)
Parentheses show percentage, Values express as meanSD.
UIP ; usual interstitial pneumonia, NSIP ; non-specific interstitial pneumonia, DAD ; diffuse alveolar damage, OP ; organizing pneu-
monia, CK ; creatine kinase, mPSL ; methylprednisolone, CyA ; cyclosporin A
*NSIP pattern in a patient changed into DAD pattern in clinical course.
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pulse and those without mPSL pulse.
Comparison of selection of therapeutic drugs be-
tween former and later times
The selection of therapeutic drugs is compared
between patients in former (Aug 2000-May 2004)
and later (Apr 2004-Oct 2006) times (Table 7). There
was no difference in the percentage of PM patients
between these two times. The percentage of patients
who received cyclosporin A was higher in later times
(58%) than in former times (27%). Patients who re-
ceived mPSL pulse therapy were also increased in
later times (42%) when compared with former times
(18%).
Adverse events and prognosis
Malignant diseases appeared in 3 patients with DM
which consisted of breast cancer, epipharyngeal
cancer and gastric cancer (Table 8). Patients with
breast cancer and gastric caner received surgical
resection of the lesion successfully. The patient with
epipharyngeal cancer received the combination ther-
apy with chemotherapy and radiation, and then was
followed in another hospital. The lesion of DM such
as myositis and IP did not change during the ther-
apy for cancer. No malignant disease was observed
in patients with PM. Six patients experienced severe
infections ; a pneumocystis pneunonia, 3 bacterial
pneumonia, a fungus infection and a miliary tuber-
culosis. A mean duration between onset of the in-
fections and the treatment is 1519 months. We ob-
served 2 deaths during the course. There is a death
due to IP by developing DAD pattern, and a death
due to miliary tuberculosis. Recurrence was ob-
served in 3 patients. The recurrence of IP was ob-
served in a patient with PM when the dose of pred-
nisolone was decreased to 7.5 mg/day, and that of
myositis was in 2 patients with DM when predni-
solone was decreased to 7 and 9 mg/day, respec-
tively (data not shown).
Table 8. Serious complications
Case No. Complications mPSLpulse
prednisolone
CyA Period(months)*The starting dose
(mg/day)
The dose at onset
(mg/day)
Case 2 Pneumocystis pneumonia () 50 40 () 2
Case 3 Bacterial pneumonia () 50 5 () 49
Case 11
Breast cancer
( + ) 60
10
( + )
20
Aspergillosis 50 2
Nocardiosis 45 3
Fungal endophthalmitis 40 3
Case 15 Bacterial pneumonia () 40 10 () 29
Case 20 Miliary tuberculosis () 100 35 () 1
Case 21
Upper pharyngal cancer
() 60
60
()
1
Bacterial pneumonia 5 33
Case 23 Gastric cancer () 20 3 () 12
period between initial treatment and appearance of complication.
mPSL ; methylprednisolone, CyA ; cyclosporin A
Table 7. Comparison of clinical course between former and later times
Number
of
patients
Sex
(M/F) Age PM/DM
PSL
+
CyA
mPSL
pulse
Muscular improvement pulmonary improvement
Muscular
symptoms CK HRCT KL-6
Aug 2000

Mar 2004
11 5/6 5912 5/6 3(27)
2
(18)
9
(100)
7
(100)
6
(67)
4
(50)
Apr 2004

Oct 2006
12 1/11 5113 4/8 7(58)
5
(42)
10
(100)
12
(100)
7
(88)
4
(80)
Parentheses show percentage, Values express as meanSD.
PM ; polymyositis, DM ; dermatomyositis, CyA ; cyclosporin A, PSL ; prednisolone, mPSL ; methylprednisolone
CK ; creatine kinase, HRCT ; high-resolution computed tomography
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DISCUSSION
In this study, clinical course of PM/DM in our
clinical department was studied comparing PM and
DM. Our study showed that 74% of patients with
PM/DM experienced IP, and its complication was
more frequent in DM patients than in PM patients.
The prevalence of IP in PM/DM has been reported
to vary between 23% and 65% (3, 7) depending on
criteria applied. The following two reasons are con-
sidered for high incidence of IP in PM/DM pa-
tients in our study. First, chest HRCT which was
known to be a sensitive test to diagnose IP was per-
formed in all of patients with PM/DM in our study.
Second, PM/DM patients with IP were transferred
from other clinics to our hospital because our labo-
ratory has majored in respiratory diseases. IP is
one of the most frequent and serious organ involve-
ments in patients with PM/DM. Arsura and Green-
berg have shown a decreased survival in patients
with IP compared with those without IP (60% at 31
months versus 76% at 60 months) (15). In this study,
however, 13 patients (76%) of PM/DM patients ex-
perienced improvement of IP ; 60% of PM patients
and 83% of DM patients, and the prognosis for IP
was in good course during follow-up periods. HRCT
demonstrated that most (65%) of patients with IP
showed NSIP pattern and less patients (24%) did
UIP pattern. Since it has been reported that patients
with UIP have poorer course in comparison with
those with NSIP (16), a better prognosis of PM/DM
patients observed in this study might be due to high
frequency of NSIP. On the other hand, previous re-
ports showed that the survival of PM-IP patients was
better than that of DM-IP (7). It has been also shown
that 44-60% of IP in PM/DM, especially DM, is re-
sistant to high-dose corticosteroid therapy and the
corticosteroid-resistant IP patients died of respira-
tory failure in a relatively short period (3). However,
in this study there was no difference in morbidity and
mortality due to IP between PM and DM though
there was a patient with DM who died of DAD
changed from NSIP. The reason for the discrepancy
between our study and previous reports is not clear,
but it may be explained by high percentages of NSIP
in DM patients in this study.
The first line of treatment in PM/DM consists
of corticosteroids. Recently, however, favorable out-
come with immunosuppressive therapy in patients
with PM/DM has been reported (5, 7, 17). Of the
immunosuppressive agents, cyclosporin A has been
shown to prolong survival of patients with PM/DM
(5, 7, 17, 18). Cyclosporin A forms a complex with
an intracytoplasmic protein, cyclophilin, and this
complex inhibits the intracellular phosphatase cal-
cineurin resulting in the inhibition of interleukin-2
release from helper T cells. This inhibition sup-
presses both proliferation and function of CD4+ T
cells. In this study, cyclosporin A was used as com-
bination with prednisolone in 10 PM/DM patients
(48%). Cyclosporin A was started in 4 patients at
the same time as prednisolone, and was started in
6 patients on the way of the course when disease ac-
tivity remained after the treatment with prednisolone
alone. The percentage of patients who received the
treatment with cyclosporin A was more in later times
(after Apr, 2004) when compared with in former
times (before Mar, 2004) which resulted from in-
creased evidence about efficacy in cyclosporin A in
PM/DM. The percentage of patients who received
mPSL pulse was also increased in later times when
compared in former times. The treatment with mPSL
pulse is increasing being used in patients with acute
and severe disease activities of PM/DM such as
active IP, and the early use of mPSL pulse is con-
sidered to be useful to control them (4). However,
whether mPSL pulse therapy results in more rapid
control of disease activity or lower cumulative doses
of prednisolone has not been determined.
In this study, 2 DM patients died during the
course ; one patient died of developing DAD, and the
other died of miliary tuberculosis. Previous reports
showed that IP is a major cause of death in patients
with PM/DM and contributes substantially to mor-
bidity and mortality especially in DM (19-21). On
the other hand, high frequency of infectious com-
plications has been shown in patients with PM/DM
(2, 22) with significant morbidity and mortality. In
PM/DM, infectious complications have been de-
scribed in up to 26% of patients (8). In this study,
patients with PM/DM experienced 8 severe infec-
tious events in 6 cases (26%). Most common events
were bacterial pneumonia and fungal infections.
These infections occurred at 1-49 months after the
initial treatment at dose of 5-50 mg/day of predni-
solone. Of them, a case died of miliary tuberculosis,
but others were healed by the treatment. Although
several factors may be implicated in increased fre-
quency of infections in PM/DM patients, the treat-
ment with immunosuppressive medications may be
one of major factors. Marie, et al. showed that risk
factors for opportunistic infections are the use of
immunosuppressive drugs, lymphopenia, and lower
serum total protein levels, and mortality rates by
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infections were as high as 27.7% in PM/DM pa-
tients with opportunistic infections (8). This study
showed that cyclosporin A and mPSL pulse were
used in more patients in later times in our hospital
which suggested the possibility of serious oppor-
tunistic infection might be increased during the
therapeutic course. Therefore, our results suggest
that patients with PM/DM presenting with factors
predictive of opportunistic infection may require
closer monitoring.
Three patients had malignant diseases which con-
sisted of breast cancer, epipharyngeal cancer and
gastric cancer. All patients had DM, and were older
than 56 y.o.. Recent reports strongly support an in-
creased risk of malignant diseases in patients with
DM, and older patients with DM are at greater risk
(10, 11, 23, 24). Hill, et al. reported that 198 (32%)
of 618 cases with DM had cancer, and of these,
115 (59%) developed a malignant disease after the
diagnosis of DM (10). On the other hand, 137 (15%)
of 914 cases with PM had cancer, which developed
after diagnosis of PM in 95 (69%)(10). Similarly,
Airio, et al. showed that the relative risk of cancer
among DM patients but not PM patients was high,
and the risk was high among patients with DM older
than 49 (11). DM patients was strongly associated
with ovarian, lung, pancreatic, stomach and colorec-
tal cencer, and non-Hodgkin lymphoma, and the
overall risk of cancer was greatest in the first 3 years
after the diagnosis, but a greater risk of malignancy
persists through all years of follow-up. (24). These
data suggest that a cancer evaluation of PM/DM
patients, especially DM patients, is important at the
initial diagnosis, and one needs to follow the patient
carefully for a number of years.
In conclusion, we have shown clinical series of
patients with PM/DM in our clinical department.
Higher frequency in complications of malignancies
and opportunistic infections was observed in patients
with DM than those with PM. All of patients who
died during the course were patients with DM. Im-
munosuppressive medications may be implicated
at least partially in increased risk of infections and
malignancies in PM/DM patients especially DM
patients. This study indicates that patients with
PM/DM may require careful monitoring in clinical
course.
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